Research Alliance Corp III Prices $75M Initial Public Offering

summarizeSummary

Research Alliance Corp III has priced its $75 million initial public offering at $10.00 per share, establishing a trust account for future business combinations and addressing its initial capital needs.

check_boxKey Events

• Initial Public Offering Priced

  Research Alliance Corp III priced its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75 million in gross proceeds.

• Sponsor Private Placement

  The company's sponsor will concurrently purchase 275,000 Class A ordinary shares at $10.00 per share, totaling $2.75 million, alongside the IPO.

• Trust Account Established

  $75 million from the offering proceeds will be deposited into a trust account, to be held until a business combination is completed or the company liquidates.

• Immediate Dilution for Public Shareholders

  Public shareholders will experience an immediate dilution of approximately 18.7% (or $1.87 per share), as the pro forma net tangible book value is $8.13 per share compared to the $10.00 offering price.

auto_awesomeAnalysis

This 424B4 filing marks the successful pricing and launch of Research Alliance Corp III's initial public offering, raising $75 million. This capital infusion is critical for the newly formed blank check company, addressing its prior "going concern" status and enabling it to pursue its objective of a business combination in the healthcare sector. While the offering provides necessary funding and is priced at the standard $10.00 per share, new public shareholders face an immediate dilution of 18.7% based on the pro forma net tangible book value. The sponsor's concurrent private placement and significant founder share holdings (acquired at a nominal price) also introduce potential conflicts of interest and further dilution for public shareholders upon a future business combination. The absence of warrants for public investors, common in many SPAC IPOs, is also a notable aspect.